Risk Factors and Adverse Events Poorly Predict Infections and Hypogammaglobulinemia in Granulomatosis with Polyangiitis Patients Receiving Rituximab

Figure 1

Correspondence analysis of adverse events during RTX maintenance. CI: chronic infection; DH: hypogammaglobulinemia leading to RTX discontinuation; HG: hypogammaglobulinemia with total Ig < 6 g/L; SI: severe infection. No_CI: absence of chronic infection; No_DH: absence of hypogammaglobulinemia leading to RTX discontinuation; No_HG: absence of hypogammaglobulinemia with total Ig < 6 g/L; No_SI: absence of severe infection. 1: men; 2: women; 3: kidney involvement; 4: no kidney involvement; 5: lung involvement; 6: no lung involvement; 7: orbital and subglottic involvement; 8: no orbital and subglottic involvement; 9: use of MTX during RTX; 10: no MTX use; 11: use of AZA during RTX; 12: no use of AZA; 13: use of MMF during RTX; 14: no use of MMF; 15: RTX maintenance with the 2 g annually regimen; 16: other maintenance regimes; 17: age under 40 y at baseline; 18: age between 40 and 55; 19: age over 55 years; 20: low IgG level prior RTX; 21: high IgG prior RTX; 22: low IgA level prior RTX; 23: high IgA prior RTX; 24: inverted CD4/CD8 ratio prior RTX; 25: normal ratio prior RTX; 26: low CYC cumulative dose; 27: high CYC cumulative dose.